Targets

Our scientific approach is based on targeting two different tumour-driving mechanisms

Androgen receptor

Signalling through this receptor is critical for prostate cancer development and progression, but inevitably resistance mechanisms evolve to current therapies.

Hox genes

A set of genes that play key roles in defining the identity of cells and tissues in early development and which therefore also have important regulatory roles in cell proliferation and survival. Our innovation focuses on inhibiting the binding of Hox proteins to PBX thereby overcoming the need to target every Hox protein.